Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Johnson & Johnson — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.73, while Johnson & Johnson trades at $260.7 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| BOTZ | JNJ | |
|---|---|---|
52-Week High | $41.63 | $267.24 |
52-Week Low | $31.99 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.81, up 1.04% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on robotics and AI, with news highlighting its role in the expanding automation theme. Key support and resistance cluster tightly around $37-$38, indicating a critical price zone.
Outlook remains positive due to structural growth in robotics and AI, though high RSI suggests near-term consolidation risk. Competition from other thematic ETFs and macroeconomic sensitivity are key risks for investors.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
